Status:
COMPLETED
Advanced Glycation End Products Are Associated With Diabetic Macular Edema
Lead Sponsor:
Hacettepe University
Conditions:
Diabetic Macular Edema
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Diabetic macular edema can develop at all stages of diabetic retinopathy, causing visual impairment and blindness. Modern diets are high in advanced glycation end products (dAGEs), derived from proces...
Detailed Description
This was a cross-sectional study was carried out in the Hacettepe University Hospital, Department of Ophthalmology, between July 2018 and February 2019. While benefiting from the results of the previ...
Eligibility Criteria
Inclusion
- Included from the study were those over the age of 18 years, with diagnosis of Type 2 DM.
Exclusion
- Excluded from the study were those under the age of 18 years, with no diagnosis of Type 2 DM, without any anti-diabetic agent, with any disease other than DME and DR that may affect the retina, with any disease that may affect the retina for the control group, with corneal, lens or vitreous opacification preventing Optical coherence tomography (OCT) withdrawal, with any systemic disease other than DM and hypertension, with a history of eye surgery, and with blindness or infection in the eye, along with those recently diagnosed with diabetes (\<1 year) and those with special diets.
Key Trial Info
Start Date :
July 7 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 10 2019
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT04468152
Start Date
July 7 2018
End Date
January 10 2019
Last Update
July 13 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hacettepe University Hospital Department of Ophthalmology Polyclinic
Ankara, Altındağ, Turkey (Türkiye), 06230